• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Gala­pa­gos snags co-pro­mo­tion rights on fil­go­tinib — just be­fore Gilead’s lock-up pact ex­pires

8 years ago
R&D
Pharma

Jnana launch­es with $50M to spot­light an un­ex­plored pro­tein ter­ri­to­ry

8 years ago
Financing
Startups

Pfiz­er's Ix­i­fi gets ap­proved as third Rem­i­cade biosim­i­lar; No­vo Nordisk li­cens­es re­MYN­D's di­a­betes pro­gram in ...

8 years ago
News Briefing

Bris­tol-My­ers teams up with Op­di­vo mak­er Ono Phar­ma­ceu­ti­cal on new I/O pro­grams

8 years ago
R&D
Pharma

The top 10 prospec­tive block­buster drug launch­es slat­ed for 2018 — Eval­u­ate

8 years ago
R&D
Pharma

Te­va ax­ing 14,000 work­ers, putting R&D and man­u­fac­tur­ing fa­cil­i­ties on the block in mas­sive re­struc­tur­ing

8 years ago
R&D
Pharma

Re­lay grabs $63M to pay for a drug dis­cov­ery trip in­to the fourth di­men­sion

8 years ago
Financing

An­dreessen drums up a $450M fund to back their vi­sion for en­gi­neer­ing bi­ol­o­gy

8 years ago
Financing
AI

Its un­der­ly­ing bi­ol­o­gy 'too com­pli­cat­ed' for fur­ther in­vest­ment, At­las-seed­ed Raze signs off

8 years ago
Startups

At­las and Or­biMed back Boston's Kyn in $49M round to pur­sue im­munome­tab­o­lism ther­a­pies

8 years ago
Financing

Eli Lil­ly high­lights key R&D cat­a­lysts for 2018; Ver­nalis and Dai­ichi Sankyo work to­geth­er on can­cer tar­gets

8 years ago
News Briefing

NEA leads a big syn­di­cate on $100M mega-round for Al­lakos

8 years ago
R&D

Dai­ichi ditch­es Nek­tar fol­low­ing can­cer drug flop

8 years ago
R&D

Sanofi faces a make-or-break year, say­ing it’s ready to put a 3-prong R&D strat­e­gy to a piv­otal test

8 years ago
R&D

Te­va sharp­ens ax, preps bru­tal cuts in R&D and across the group in face of crush­ing debt

8 years ago
R&D
Pharma

Yer­voy in­ven­tor's on­col­o­gy start­up Pi­o­nyr gets $62M for tu­mor-fight­ing tech

8 years ago
Financing

Re­gen­eron, Sanofi are ready to de­but the 6th PD-1/L1. Is it still pos­si­ble to stand out from the grow­ing crowd?

8 years ago
R&D

When can FDA 'refuse to file' NDAs and BLAs? New draft guid­ance ex­plains

8 years ago
Pharma

SEC charges Provec­tus found­ing CEO Dees with loot­ing mil­lions for girl­friends’ cos­met­ic surg­eries, trav­el and more

8 years ago
People

Medi­gene, RXi strike re­search deal to im­prove TCRs; Bris­tol-My­ers pays PsiOxus $15M mile­stone for tri­al-ready ...

8 years ago
News Briefing

Ex-Dez­i­ma CEO co-founds NASH start­up, fly­ing in­to Phase IIB with €25 mil­lion

8 years ago
Startups

Sanofi's R&D day pos­es some big chal­lenges as skep­tics cir­cle in wake of a Deng­vax­ia fi­as­co

8 years ago
Bioregnum
Opinion

Aduro buries an­oth­er can­cer vac­cine af­ter CRS-207 joins the line­up of clin­i­cal dis­as­ters

8 years ago
R&D

#ASH17: Ab­b­Vie, Roche boast stel­lar PhI­II leukemia da­ta for a “break­through” com­bo with block­buster am­bi­tions

8 years ago
R&D
First page Previous page 1062106310641065106610671068 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.